Circulating Biomarkers for Alzheimer's Disease: Unlocking the diagnostic potential in Low-and Middle-Income Countries, focusing on Africa

Neurodegener Dis. 2024 Mar 29. doi: 10.1159/000538623. Online ahead of print.ABSTRACTBACKGROUND: Alzheimer's disease (AD) is emerging as a significant public health challenge in Africa, with predictions indicating a tripling in incidence by 2050. The diagnosis of AD on the African continent is notably difficult, leading to late detection that severely limits treatment options and significantly impacts the quality of life for patients and their families.SUMMARY: This review focuses on the potential of high-sensitivity specific blood biomarkers as promising tools for improving AD diagnosis and management globally, particularly in Africa. These advances are particularly pertinent in the continent, where access to medical and technical resources is often limited.KEY MESSAGES: Identifying precise, sensitive, and specific blood biomarkers could contribute to the biological characterization and management of Alzheimer's disease in Africa. Such advances promise to improve patient care and pave the way for new regional opportunities in pharmaceutical research and drug trials on the continent for Alzheimer's disease.PMID:38555638 | DOI:10.1159/000538623
Source: Neuro-Degenerative Diseases - Category: Neurology Authors: Source Type: research